We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cell Makeup Affects Immunity in the Elderly

By Biotechdaily staff writers
Posted on 29 May 2002
New evidence helps to explain why the immune system of elderly people is less capable of fighting off infections. More...
In a study of transgenic mice, researchers from National Jewish Medical and Research Center (Denver CO, USA) found that as the body ages it becomes increasingly dependent on less effective antigen-experienced B cells. These do not counter infection as well as naive B cells, which predominate in younger individuals. The findings appear in the May 15, 2002, issue of The Journal of Immunology.

Researchers had been puzzled by the fact that although production of new B cells declines with age, the number of circulating B cells remains nearly constant. Dr. John Cambier and his colleagues hypothesized that older mice maintain high B-cell levels by stockpiling antigen-experienced B cells. Exposure to foreign pathogens helps them live longer than naive B cells, which usually die after five to six weeks if they do not encounter a pathogen.

Antibodies secreted by antigen-experienced B cells are made to fight a previous pathogen and generally do not bind strongly to the current one. Naive B cells can mount a more potent defense because they custom-tailor their antibodies to the current pathogen, allowing the antibodies to bind strongly.

The investigators examined the B cells in mice less than three months of age and mice older than 22 months. They used a number of cell characteristics, including cell-surface receptors and antibody expression, to distinguish antigen-experienced B cells from naive ones. One kind of naive B cell, called a follicular cell, decreased from an average of 70% of the B-cell population in young mice to 32% in older mice. In another analysis, results indicated that only about 5% of the B cells in young mice were antigen-experienced, but they accounted for 76% of the B cells in older mice. "These numbers are averages,” said co-author Sarah Johnson. "The B cell populations of individual mice varied, with some retaining large numbers of naive B cells and other carrying almost none. The mice with many naive B cells would presumably be better at fighting off infections.”

In a later study, hematopoietic stem cells from young mice were transplanted into old mice. Initial results suggest that the transplantation restores the B cell population to a younger, more naive and adaptable profile.




Related Links:
National Jewish Medical and Research Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.